Moreover, early-phase clinical studies have demonstrated promising antitumor activity and restoration of antitumor immunity with combinations of MEK inhibitors and anti-PD-L1 antibodies in patients with BRAFV600 wild-type advanced melanoma (13). Here, MAP2K7 is linked to melanoma.